Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients

Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non-diabetic HF outpatients is unknown. Methods: Adult non-diabetic HF patients with a left ventricular ejection fraction (LVEF)...

Descripción completa

Detalles Bibliográficos
Autores principales: Reis, João, Teixeira, Ana Rita, Gonçalves, António Valentim, Moreira, Rita Ilhão, Silva, Tiago Pereira, Timóteo, Ana Teresa, Ferreira, Rui Cruz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144118/
https://www.ncbi.nlm.nih.gov/pubmed/35629062
http://dx.doi.org/10.3390/jcm11102935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144118/
https://www.ncbi.nlm.nih.gov/pubmed/35629062
http://dx.doi.org/10.3390/jcm11102935

Ejemplares similares